Indications › Obesity & overweight › liraglutide

liraglutide in obesity & overweight

liraglutide is approved in the US for obesity & overweight, and has 84 trials on file here in this condition. 72 of them are phase 3 or later. The next scheduled result is 2027-02-01.

84 registered trials study liraglutide (Saxenda, Victoza, Xultophy) in obesity & overweight, 7 of them still active and 1 in phase 3. The next is due to report 2027-08-31.

Trials on file: 84
Active: 7
Active phase 3: 1
Participants in active trials: 1,382
Sponsors: 54
Scheduled readouts: 1

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completion	Trial	Phase	Participants
2027-08-31	RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. NCT07301437 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine	P4	120

All trials on file

Every registered trial of liraglutide grouped under obesity & overweight, largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes NCT01272219	Completed	P3	Novo Nordisk A/S
Liraglutide Treatment in Obese Infertile PCOS Women NCT06742710	Recruiting	P4	Peking University Third Hospital
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes NCT01272232	Completed	P3	Novo Nordisk A/S
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. NCT03856047	Completed	P2	Novo Nordisk A/S
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes NCT00422058	Completed	P2	Novo Nordisk A/S
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants NCT03486392	Completed	P2	Janssen Research & Development, LLC
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance NCT00781937	Completed	P3	Novo Nordisk A/S
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients NCT04605861	Completed	P3	Shanghai Zhongshan Hospital
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin NCT02963922	Completed	P3	Novo Nordisk A/S
Saxenda in Obesity Services (STRIVE Study) NCT03036800	Completed	P4	University of Leicester
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea NCT01557166	Completed	P3	Novo Nordisk A/S
Cardiovascular Effects of GLP-1 Receptor Activation NCT03101930	Completed	P4	Vanderbilt University Medical Center
Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities NCT04487743	Unknown	P3	Xiangya Hospital of Central South University
Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities NCT04525300	Unknown	P3	Xiangya Hospital of Central South University
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting NCT02963935	Completed	P3	Novo Nordisk A/S
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity NCT02918279	Completed	P3	Novo Nordisk A/S
Impact of Liraglutide 3.0 on Body Fat Distribution NCT03038620	Completed	P4	University of Texas Southwestern Medical Center
Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet NCT04122716	Unknown	P4	Signe Torekov
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity NCT05111912	Completed	P2	Sciwind Biosciences APAC CO Pty. Ltd.
Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity NCT03799198	Completed	P4	Novo Nordisk A/S
Individualized Obesity Pharmacotherapy NCT03374956	Completed	P3	Mayo Clinic
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility NCT05952882	Unknown	P3	Mỹ Đức Hospital
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) NCT03087032	Recruiting	P4	The First Affiliated Hospital of Xiamen University
Lifestyle Modification and Liraglutide NCT02911818	Completed	P4	University of Pennsylvania
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients NCT03671733	Unknown	P3	Xiangya Hospital of Central South University
Liraglutide 3 mg for Knee Osteoarthritis NCT02905864	Completed	P4	Henrik Gudbergsen
Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance NCT02928614	Completed	P4	Henrik Gudbergsen
Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance NCT02928679	Completed	P4	Henrik Gudbergsen
Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance NCT02931383	Completed	P4	Henrik Gudbergsen
Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity NCT03523273	Completed	P2	Michael Camilleri, MD
Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery NCT03048578	Completed	P4	NYU Langone Health
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. NCT07301437	Not yet recruiting	P4	The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease NCT06501326	Unknown	P4	Affiliated Hospital of Nantong University
Liraglutide in Type 1 Diabetes NCT01612468	Completed	P4	Steno Diabetes Center Copenhagen
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery NCT07374445	Completed	P4	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes NCT02014740	Completed	P4	University of Miami
Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes NCT02503943	Unknown	P4	Third Affiliated Hospital of Third Military Medical University
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS NCT03480022	Completed	P3	Woman's
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity NCT04775082	Active, not recruiting	P3	Novo Nordisk A/S
EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial NCT04531176	Terminated	P4	The Cleveland Clinic
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone NCT06865365	Not yet recruiting	P4	Medical University of Vienna
Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) NCT02055014	Unknown	P4	Sandwell & West Birmingham Hospitals NHS Trust
Adding Liraglutide to High Dose Insulin: Breaking the Cycle NCT01505673	Completed	P4	Ildiko Lingvay
Effect of Liraglutide on Microbiome in Obesity NCT04046822	Unknown	P4	Federico II University
Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response NCT03341429	Completed	P4	University College, London
Reward Mechanisms in Obesity NCT03347890	Completed	P4	Zoltan Pataky
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS NCT03151005	Completed	P4	Xinqiao Hospital of Chongqing
Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) NCT03158805	Completed	P2	Lindner Center of HOPE
Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients NCT03986008	Unknown	P3	Xiangya Hospital of Central South University
Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome NCT02527200	Completed	P3	Novo Nordisk A/S
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes NCT01725126	Completed	P2	GlaxoSmithKline
Preoperative Condition in Giant Obese Patients NCT02616003	Completed	P4	Sana Klinikum Offenbach
GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations NCT02082496	Completed	P2	University of Copenhagen
Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes NCT02674893	Terminated	P4	Centre Hospitalier Universitaire Dijon
Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy NCT03115424	Completed	P3	Mayo Clinic
PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome NCT02187250	Completed	P4	University Medical Centre Ljubljana
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy NCT04575194	Unknown	P4	National and Kapodistrian University of Athens
LIROH - Liraglutide for Obesity in HIV NCT06438146	Unknown	P4	Brigham and Women's Hospital
Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity NCT02647944	Completed	P2	Mayo Clinic
Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome NCT02483299	Completed	P4	University Medical Centre Ljubljana

See the full record for liraglutide, or every molecule being studied in obesity & overweight. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.